Jubilant Pharmova Executive and Leadership Team

Harsher Singh, the Chief Executive Officer - Jubilant Radiopharma at Jubilant Pharmova, directs the global expansion of specialized diagnostic and therapeutic radiopharmaceutical products. Singh oversees the integration of complex supply chains required for time-sensitive medical isotopes, ensuring consistent delivery to healthcare providers across North American and European markets. By aligning research initiatives with clinical demand, the Chief Executive Officer - Jubilant Radiopharma drives the development of next-generation imaging agents. Harsher Singh maintains rigorous compliance with international regulatory standards, safeguarding product quality throughout the manufacturing lifecycle. This leadership role involves constant collaboration with the Board to identify emerging market opportunities in nuclear medicine. Through strategic investment in advanced production facilities, the Chief Executive Officer - Jubilant Radiopharma secures a competitive advantage in the biopharmaceutical sector. Ultimately, Singh optimizes operational workflows to enhance patient access to critical diagnostic tools while maintaining high profitability margins for the division.

Ashish Mukkirwar, the President & Chief Financial Officer at Jubilant Pharmova, manages the financial health and capital allocation strategies for the entire organization. Mukkirwar oversees fiscal planning, budgeting, and investor relations, ensuring transparency and long-term value creation for stakeholders. By directing financial risk management, the President & Chief Financial Officer secures the capital required for research and development investments in new drug pipelines. Ashish Mukkirwar monitors global market trends to inform strategic decision-making regarding mergers, acquisitions, and divestitures. This leadership role involves constant collaboration with the Board to maintain a robust balance sheet and optimize cash flow across international operations. Through rigorous financial oversight, the President & Chief Financial Officer ensures compliance with international accounting standards and regulatory requirements. Mukkirwar drives cost-optimization programs that enhance operational margins without compromising product quality. By aligning financial resources with the company's core mission, the President & Chief Financial Officer supports sustainable growth and market leadership in the competitive biopharmaceutical landscape.

Arul Ramakrishnan, the Chief Operating Officer at Jubilant Pharmova, manages the end-to-end manufacturing processes and supply chain logistics for the entire biopharmaceutical portfolio. Ramakrishnan coordinates cross-functional teams to streamline production cycles, reducing lead times for essential pharmaceutical ingredients. Overseeing large-scale manufacturing operations, the Chief Operating Officer ensures strict adherence to global quality benchmarks and safety protocols. Arul Ramakrishnan implements lean manufacturing methodologies to minimize waste and maximize output efficiency across all production sites. This role requires constant interaction with the executive leadership team to align operational capacity with shifting market demands. By optimizing resource allocation, the Chief Operating Officer supports the company's mission to provide affordable, high-quality medicine. Ramakrishnan drives continuous improvement initiatives, fostering a culture of operational excellence that sustains long-term growth. Through meticulous oversight of technical infrastructure, the Chief Operating Officer maintains the integrity of the global supply chain, ensuring consistent product availability for patients worldwide.

Shantanu Jha, the Group Chief Human Resources Officer at Jubilant Pharmova, architects the organizational design and talent acquisition strategies necessary to support a global biopharmaceutical workforce. Jha directs the implementation of performance management systems that align individual contributions with the broader corporate mission of patient-focused innovation. Overseeing leadership development programs, the Group Chief Human Resources Officer cultivates a pipeline of high-potential talent capable of navigating the complexities of the pharmaceutical industry. Shantanu Jha manages compensation structures and employee engagement initiatives to retain top-tier scientific and operational experts. This leadership role involves close coordination with the executive team to foster an inclusive corporate culture that promotes safety and ethical conduct. By standardizing human capital policies across international regions, the Group Chief Human Resources Officer ensures organizational agility. Jha drives initiatives that prioritize employee well-being, directly impacting productivity and long-term retention. Through strategic workforce planning, the Group Chief Human Resources Officer supports the company's ability to scale operations effectively.